A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Pazopanib (Primary) ; Paclitaxel
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms TAPAZ
- 23 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
- 21 Oct 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 16 Mar 2015 New trial record